Natural Alternatives International, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US6388423021
USD
3.69
0.27 (7.89%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

25.98 k

Shareholding (Sep 2025)

FII

0.68%

Held by 6 FIIs

DII

86.63%

Held by 13 DIIs

Promoter

0.00%

How big is Natural Alternatives International, Inc.?

22-Jun-2025

As of Jun 18, Natural Alternatives International, Inc. has a market capitalization of 32.36 million, with net sales of 125.35 million and a net profit of -8.23 million over the latest four quarters. As of Jun 24, the company reported shareholder's funds of 82.59 million and total assets of 171.74 million.

Market Cap: As of Jun 18, Natural Alternatives International, Inc. has a market capitalization of 32.36 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 125.35 million and a net profit of -8.23 million.<BR><BR>Balance Sheet Snapshot: As of Jun 24, the company reported shareholder's funds of 82.59 million and total assets of 171.74 million.

View full answer

What does Natural Alternatives International, Inc. do?

22-Jun-2025

Natural Alternatives International, Inc. formulates, manufactures, and markets nutritional supplements in the Pharmaceuticals & Biotechnology industry, with a market cap of $32.36 million and quarterly net sales of $29 million but a net profit of -$2 million as of March 2025.

Overview: <BR>Natural Alternatives International, Inc. is a formulator, manufacturer, and marketer of nutritional supplements operating in the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 29 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 32.36 Million (Micro Cap)<BR><BR>Key Metrics: <BR>Debt Equity: 0.03 <BR>Return on Equity: -10.35% <BR>Price to Book: 0.42<BR><BR>Contact Details: <BR>Address: 1535 Faraday Ave, CARLSBAD CA: 92008-7319 <BR>Tel: 1 619 7447340 <BR>Fax: 1 760 7449589 <BR>Website: http://www.nai-online.com

View full answer

Should I buy, sell or hold Natural Alternatives International, Inc.?

22-Jun-2025

Who are in the management team of Natural Alternatives International, Inc.?

22-Jun-2025

As of March 2022, the management team of Natural Alternatives International, Inc. includes Mr. Mark LeDoux as Chairman and CEO, along with independent directors Mr. Joe Davis, Mr. Alan Dunn, Mr. Alan Lane, and Mr. Lee Weldon.

As of March 2022, the management team of Natural Alternatives International, Inc. includes Mr. Mark LeDoux, who serves as the Chairman of the Board of Directors and Chief Executive Officer. Additionally, the board features several independent directors: Mr. Joe Davis, Mr. Alan Dunn, Mr. Alan Lane, and Mr. Lee Weldon. <BR><BR>In summary, as of March 2022, the key members of the management team are Mr. Mark LeDoux and a group of independent directors including Mr. Joe Davis, Mr. Alan Dunn, Mr. Alan Lane, and Mr. Lee Weldon.

View full answer

Is Natural Alternatives International, Inc. overvalued or undervalued?

20-Sep-2025

As of February 13, 2024, Natural Alternatives International, Inc. is considered risky and overvalued due to significant losses and poor return metrics, with a much lower EV to EBITDA ratio compared to peers, and a 1-year stock return of -49.46% versus the S&P 500's 17.14%.

As of 13 February 2024, the valuation grade for Natural Alternatives International, Inc. has moved from expensive to risky, indicating a deteriorating outlook. The company appears to be overvalued given its significant losses and negative return metrics. Key ratios include a Price to Book Value of 0.42, an EV to Sales ratio of 0.28, and an EV to EBITDA of -7.72, all of which suggest that the company's valuation does not align well with its financial performance.<BR><BR>In comparison to its peers, Natural Alternatives International, Inc. has a much lower EV to EBITDA ratio than Chromadex Corp. at 36.5633 and USANA Health Sciences, Inc. at 4.7297, both of which are categorized as expensive. The company's stock has underperformed significantly against the S&P 500, with a 1-year return of -49.46% compared to the index's 17.14%, reinforcing the notion of its overvaluation.

View full answer

Is Natural Alternatives International, Inc. technically bullish or bearish?

20-Sep-2025

As of August 25, 2025, Natural Alternatives International, Inc. is in a mildly bearish trend, indicated by bearish daily moving averages and Bollinger Bands, despite some mildly bullish MACD signals, with a year-to-date return of -24.59% compared to the S&P 500's 12.22%.

As of 25 August 2025, the technical trend for Natural Alternatives International, Inc. has changed from sideways to mildly bearish. The current stance is bearish, driven by daily moving averages indicating bearish momentum and weekly Bollinger Bands also signaling a bearish trend. The Dow Theory and On-Balance Volume (OBV) both reflect a mildly bearish outlook on the weekly and monthly time frames. <BR><BR>Despite the MACD showing mildly bullish signals on both weekly and monthly charts, the overall sentiment remains bearish due to the prevailing indicators. The stock has underperformed significantly compared to the S&P 500, with a year-to-date return of -24.59% versus the S&P 500's 12.22%, and a one-year return of -49.46% compared to the S&P 500's 17.14%.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

Poor Management Efficiency with a low ROE of 6.24%

  • The company has been able to generate a Return on Equity (avg) of 6.24% signifying low profitability per unit of shareholders funds
2

Poor long term growth as Operating profit has grown by an annual rate -55.49% of over the last 5 years

 
3

The company has declared Negative results for the last 14 consecutive quarters

4

Risky - Negative EBITDA

5

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 27 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.08

stock-summary
Return on Equity

-14.75%

stock-summary
Price to Book

0.39

Revenue and Profits:
Net Sales:
37 Million
(Quarterly Results - Sep 2025)
Net Profit:
0 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-3.15%
0%
-3.15%
6 Months
-12.56%
0%
-12.56%
1 Year
-43.23%
0%
-43.23%
2 Years
-51.32%
0%
-51.32%
3 Years
-64.99%
0%
-64.99%
4 Years
-73.68%
0%
-73.68%
5 Years
-48.25%
0%
-48.25%

Natural Alternatives International, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
2.40%
EBIT Growth (5y)
-55.49%
EBIT to Interest (avg)
3.73
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
0.03
Sales to Capital Employed (avg)
1.40
Tax Ratio
23.07%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
34.45%
ROCE (avg)
9.25%
ROE (avg)
6.24%

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.42
EV to EBIT
-3.83
EV to EBITDA
-7.72
EV to Capital Employed
0.44
EV to Sales
0.28
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-11.49%
ROE (Latest)
-10.35%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 7 Schemes (12.69%)

Foreign Institutions

Held by 6 Foreign Institutions (0.68%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 10.68% vs 17.42% in Jun 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 95.83% vs -227.27% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "37.30",
          "val2": "33.70",
          "chgp": "10.68%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.10",
          "val2": "0.60",
          "chgp": "83.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "-1.50",
          "chgp": "93.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.30",
          "val2": "-7.20",
          "chgp": "95.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-0.50%",
          "val2": "-17.30%",
          "chgp": "1.68%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2025 is 13.88% vs -27.52% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2025 is -88.89% vs -388.00% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "129.60",
          "val2": "113.80",
          "chgp": "13.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.60",
          "val2": "-3.60",
          "chgp": "27.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.90",
          "val2": "0.40",
          "chgp": "125.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.80",
          "val2": "-0.20",
          "chgp": "-800.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.60",
          "val2": "-7.20",
          "chgp": "-88.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-55.10%",
          "val2": "-72.70%",
          "chgp": "1.76%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQstock-summary

Sep'25
Jun'25
Change(%)
Net Sales
37.30
33.70
10.68%
Operating Profit (PBDIT) excl Other Income
1.10
0.60
83.33%
Interest
0.20
0.20
Exceptional Items
-0.10
-1.50
93.33%
Consolidate Net Profit
-0.30
-7.20
95.83%
Operating Profit Margin (Excl OI)
-0.50%
-17.30%
1.68%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2025 is 10.68% vs 17.42% in Jun 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is 95.83% vs -227.27% in Jun 2025

Annual Results Snapshot (Consolidated) - Jun'25stock-summary

Jun'25
Jun'24
Change(%)
Net Sales
129.60
113.80
13.88%
Operating Profit (PBDIT) excl Other Income
-2.60
-3.60
27.78%
Interest
0.90
0.40
125.00%
Exceptional Items
-1.80
-0.20
-800.00%
Consolidate Net Profit
-13.60
-7.20
-88.89%
Operating Profit Margin (Excl OI)
-55.10%
-72.70%
1.76%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Jun 2025 is 13.88% vs -27.52% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jun 2025 is -88.89% vs -388.00% in Jun 2024

stock-summaryCompany CV
About Natural Alternatives International, Inc. stock-summary
stock-summary
Natural Alternatives International, Inc.
Pharmaceuticals & Biotechnology
Natural Alternatives International, Inc. is a formulator, manufacturer and marketer of nutritional supplements. The Company operates through three segments: private-label contract manufacturing, patent and trademark licensing, and branded products. The private-label contract manufacturing segment primarily relates to the provision of private-label contract manufacturing services to companies that market and distribute nutritional supplements and other healthcare products. The patent and trademark licensing segment primarily includes direct raw material sales and royalty income from its license and supply agreements associated with the sale and use of beta-alanine under its CarnosSyn trade name. The branded products segment relates to the marketing and distribution of branded nutritional supplements and consists primarily of the products sold under its Pathway to Healing product line.
Company Coordinates stock-summary
Company Details
1535 Faraday Ave , CARLSBAD CA : 92008-7319
stock-summary
Tel: 1 619 7447340
stock-summary
Registrar Details